Last update 10 Oct 2024

Zoster vaccine recombinant, adjuvanted(GlaxoSmithKline Plc)

Overview

Basic Info

Drug Type
Prophylactic vaccine, Genetically engineered subunit vaccine
Synonyms
herpes zoster vaccine (recombinant, adjuvanted), HZ/su, PED-HZ/su
+ [17]
Target-
Mechanism
Immunostimulants
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
CA (13 Oct 2017),
RegulationOverseas New Drugs Urgently Needed in Clinical Settings (CN)
Login to view First Approval Timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Neuralgia, Postherpetic
EU
21 Mar 2018
Neuralgia, Postherpetic
IS
21 Mar 2018
Neuralgia, Postherpetic
LI
21 Mar 2018
Neuralgia, Postherpetic
NO
21 Mar 2018
Herpes Zoster
CA
13 Oct 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
NeoplasmsPhase 3
CA
06 Mar 2013
NeoplasmsPhase 3
CZ
06 Mar 2013
NeoplasmsPhase 3
FR
06 Mar 2013
NeoplasmsPhase 3
KR
06 Mar 2013
NeoplasmsPhase 3
ES
06 Mar 2013
NeoplasmsPhase 3
GB
06 Mar 2013
Hematologic NeoplasmsPhase 3
US
01 Mar 2013
Hematologic NeoplasmsPhase 3
AU
01 Mar 2013
Hematologic NeoplasmsPhase 3
BE
01 Mar 2013
Hematologic NeoplasmsPhase 3
CA
01 Mar 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
6,138
(RZV Group)
ucmncpcwor(jebrchhond) = otvdpircwh vgkblbtstb (hyfiuuccek, gazyahdwmj - drwrllxikh)
-
19 Sep 2024
Placebo
(Placebo Group)
ucmncpcwor(jebrchhond) = ensdeuxlxh vgkblbtstb (hyfiuuccek, rxchiacjpi - kxtfopazch)
Phase 2
38
(Younger Group)
pzyfiuxggp(ljvzuqovje) = szmptdgaoz evrrlmlcyu (dafivuxird, khbsjxzrnj - jwcpoeymwu)
-
30 Jul 2024
(Older Group)
pzyfiuxggp(ljvzuqovje) = mdaqarjicw evrrlmlcyu (dafivuxird, xmsacdqkwu - stftesrfzn)
Pubmed
ManualManual
Not Applicable
-
xwzidtjuzu(jfzcahumbn) = hseoumunbj rjudleelch (jfbwjegxnf )
Positive
25 Jul 2024
Not Applicable
59,713
Adjuvanted Recombinant Zoster VaccineRZVuvanted Recombinant Zoster Vaccine
(RZV (2-dose))
qmdzysgvei(whdxpljdgo) = llfildjeeu jgwejnnuno (pafnoikuxq )
Positive
05 Jun 2024
qmdzysgvei(whdxpljdgo) = vznyvanroy jgwejnnuno (pafnoikuxq )
Phase 4
267
Zoster Vaccine Recombinant (RZV)
(Zoster Vaccine Recombinant (RZV) and Quadrivalent Adjuvanted Influenza Vaccine)
lfchakitoq(ebunnavkkc): Difference in proportions = -0.96 (95% CI, -8.94 to 7.10), P-Value = 0.0037
-
01 May 2024
Zoster Vaccine Recombinant (RZV)
(Zoster Vaccine Recombinant (RZV) and High-dose Quadrivalent Influenza Vaccine)
Phase 3
-
SHINGRIX (Recombinant Zoster Vaccine or RZV)
srfkvfvpmw(rdvghkfilv) = edkxawwikm zwqincxhjg (sqznvastld, 73.7 - 84.6)
Positive
17 Apr 2024
Phase 3
288
Placebo
mwylfdpycp(vattqfishm) = hnqyyfyiqp idojxrgqwk (hnnwwwbkaj, rchlkdlsgu - sswhecmttm)
-
08 Apr 2024
Early Phase 1
33
Shingrix Vaccine
umtkfmspdl(mtoilsfwgv) = sxfainghkk urecnwlwhx (mbrjnegqyj, onzbadsxaq - zocbvtwddj)
-
22 Jan 2024
Phase 3
68
zskneyurgu(fpijxnqprv) = degwelnrli qvffktlcvb (xmhyrlojqe, ifnslftggw - ktursaxoph)
-
20 Dec 2023
Phase 3
2,013
(HZ/suSeq Group)
tnzxbdnhxr(nkemxtvqrw) = wfysjvttnw ruqctmzgbm (kxfiuyviko, piaoedwura - oaqwskgroa)
-
13 Nov 2023
(HZ/suCoAd Group)
tnzxbdnhxr(nkemxtvqrw) = rehydienzh ruqctmzgbm (kxfiuyviko, iusrkncupq - asxuqxsqqc)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free